Back to Journals » Vascular Health and Risk Management » Volume 16

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date

Authors Jia X, Koh S, Al Rifai M, Blumenthal RS, Virani SS

Received 3 November 2019

Accepted for publication 28 December 2019

Published 9 January 2020 Volume 2020:16 Pages 1—10

DOI https://doi.org/10.2147/VHRM.S210149

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Pietro Scicchitano


Xiaoming Jia,1,* Stephanie Koh,1,* Mahmoud Al Rifai,1 Roger S Blumenthal,2 Salim S Virani1,3,4

1Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; 2The Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD, USA; 3Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, Houston, TX, USA; 4Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

*These authors contributed equally to this work

Correspondence: Salim S Virani
Health Services Research and Development, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, TX 77030, USA
Tel +1 713-440-4410
Email virani@bcm.edu

Abstract: Icosapent ethyl is a highly purified formulation of eicosapentaenoic acid, a type of omega-3 fatty acid contained in fish oil. While omega-3 fatty acids have long been thought to have cardioprotective benefits, the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) has helped to establish icosapent ethyl as an evidence-based therapy for risk reduction of atherosclerotic cardiovascular disease (ASCVD). REDUCE-IT, however, was by no means an overnight success story. Close examination of the evidence shows that the trial was a culmination of many lessons learned from previous studies. The purpose of this manuscript is to review contemporary evidence of icosapent ethyl in ASCVD risk reduction and the clinical implication of this promising therapy.

Keywords: omega-3 fatty acids, icosapent ethyl, eicosapentaneoic acid, cardiovascular outcome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]